Amgen appoints David W. Gibbs to its board of directors

Amgen said Gibbs will serve on the board's Audit Committee and Compensation and Management Development Committee.

GetSignal Amgen Inc. AMGN

On October 26, 2026, Amgen's board of directors appointed David W. Gibbs as a director, effective immediately. Gibbs served as chief executive officer of Yum! Brands, Inc. from 2020 to September 2025 and as a Yum! Brands director from 2019 to September 2025. Since October 2025, he has served as an advisor to Yum! Brands.

Gibbs has been a director of Under Armour, Inc. since 2021, where he chairs the Human Capital and Compensation Committee, and a director of PepsiCo, Inc. since 2026, where he serves on the Audit Committee. He holds a bachelor's degree in mathematical science from Johns Hopkins University and a Master of Business Administration degree from Duke University's Fuqua School of Business.

Amgen said Gibbs will serve on the board's Audit Committee and its Compensation and Management Development Committee. Amgen said that, following the appointment, the board will have 13 directors, 12 of whom are independent.

Amgen said Gibbs will receive the company's standard non-employee director compensation, prorated through December 31, 2026, including an annual cash retainer of $115,000 and committee meeting retainers of $12,500. Amgen also said Gibbs will receive a prorated 7/12 portion of its annual grant of fully vested restricted stock units on the second business day after the release of its 2026 third-quarter earnings.

Key facts

Appointed
October 26, 2026, effective immediately
Committees
Audit Committee; Compensation and Management Development Committee
Board size after appointment
13 directors, 12 of whom are independent
Annual cash retainer
$115,000, prorated through December 31, 2026
Annual restricted stock unit grant
Prorated 7/12, on the second business day after release of 2026 third-quarter earnings

All AMGN news

Sources: Form 8-K filed October 27, 2026, and the company's release on PR Newswire, October 26, 2026.

Written by GetSignal with AI from the company's press release.

Not investment advice.

Follow Amgen on GetSignal

Its filings, insider trades and company news in one feed. Free on iPhone and Android.

Download on the App Store Get it on Google Play